Why don’t you ever comment on the specifics of the company. The generic biotech environment is not necessarily relevant to us. There are big deals out there -sure & I accept that. However the “elected board” are watering down the potential opportunities in their commentary. There is the cashflow concern & the timing of possible delay announcemts visa-vie need for possible CR. We will inevitably need a deal so how do you envisage that deal could look? Will the “elected board” bend over to simply get us over the line & kick the can down the road. Or will they seek to maximise SH value? Without “deal” we will not get anywhere near the SP guesses you mention - on the science alone.
Why don’t you ever comment on the specifics of the company. The...
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |